
Anika Therapeutics (ANIK) Stock Forecast & Price Target
Anika Therapeutics (ANIK) Analyst Ratings
Bulls say
Anika Therapeutics is a leading company in the early intervention orthopedics space with a diverse product portfolio and strong partnerships. The company's recent financial results beat expectations, with revenue coming in higher than anticipated and a significant increase in share repurchases. The upcoming transition in leadership to current CFO and COO, Stephen Griffin, is expected to bring continued operational improvements and a positive impact on investor confidence. Analysts also point to the potential success of the final PMA module for Hyalofast, a product for cartilage repair that recently filed its final FDA submission. With a strong balance sheet and expected revenue growth in the commercial channel, Anika is well-positioned for long-term success and we maintain an OUTPERFORM rating with a price target of $17.
Bears say
Anika Therapeutics is facing potential delays in the FDA approval process for their product Cingal, which could hinder revenue growth for the next few years. Additionally, the company's focus on internal investment and share repurchases may limit their ability to make necessary investments for future growth. Finally, their current valuation is modest and does not account for potential risks in the approval process, making their risk/reward profile unappealing.
This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Anika Therapeutics (ANIK) Analyst Forecast & Price Prediction
Start investing in Anika Therapeutics (ANIK)
Order type
Buy in
Order amount
Est. shares
0 shares